Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00492726
Recruitment Status : Completed
First Posted : June 27, 2007
Results First Posted : March 3, 2010
Last Update Posted : November 7, 2014
Sponsor:
Information provided by (Responsible Party):
Bayer

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A study to compare the safety and efficacy of moxifloxacin to ertapenem in patients with intra-abdominal infections.

Condition or disease Intervention/treatment Phase
Infection Drug: Moxifloxacin (Avelox, BAY12-8039) Drug: Ertapenem intravenous Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 804 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Double-dummy, Double-blind, Multicenter Trial Comparing the Safety and Efficacy of Intravenous Moxifloxacin 400 mg IV QD 24 Hours to That of Ertapenem 1.0 g IV QD 24 Hours for 5 to 14 Days for the Treatment of Subjects With Complicated Intra-abdominal Infections (PROMISE Study)
Study Start Date : July 2006
Actual Primary Completion Date : February 2009
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Moxifloxacin (Avelox, BAY12-8039)
Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.
 Drug: Moxifloxacin (Avelox, BAY12-8039)
Moxifloxacin, 400mg, administered intravenously once daily
Active Comparator: Ertapenem
Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.
 Drug: Ertapenem intravenous
Active treatment: Ertapenem 1.0g, administered intravenously once daily


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population [ Time Frame: 21 to 28 days after completion of study drug therapy ]
    Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.


Secondary Outcome Measures :
  1. Number of Subjects Achieving Clinical Improvement During Treatment in the Per Protocol Population [ Time Frame: During treatment at day 5 +/- 1 day ]
    Clinical improvement = Reduction in the severity and/or number of signs and symptoms of infection.Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.

  2. Number of Subjects Achieving Bacteriological Success During Treatment in the Per Protocol Population With Causative Organism(s) [ Time Frame: During treatment at day 5 +/- 1 day ]
    Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection'.

  3. Number of Subjects Achieving Clinical Cure at End of Therapy (EOT) Visit in the Per Protocol Population [ Time Frame: after 5 - 14 days of therapy ]
    Clinical cure = resolution/improvement of clinical signs and symptoms related to the infection without wound infection requiring systemic antibiotic treatment. Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.

  4. Number of Subjects Achieving Bacteriological Success at EOT Visit in the Per Protocol Population With Causative Organism(s) [ Time Frame: After 5 - 14 days of therapy ]
    Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection'.

  5. Number of Subjects Achieving Bacteriological Success at TOC Visit in the Per Protocol Population With Causative Organism(s) [ Time Frame: 21 - 28 days after end of therapy ]
    Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection' - additionally, any recurrence or reinfection was treated as bacteriological failure at TOC.

  6. Number of Subjects Achieving Clinical Cure at TOC Visit in the Per Protocol Population With Causative Organism(s) [ Time Frame: 21 - 28 days after end of therapy ]
    Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.

  7. Number of Subjects Who Died Due to Intra-abdominal Infections [ Time Frame: 21 - 28 days after end of treatment at TOC Visit ]
    Number of subjects who had died due to intra abdominal infections by the time of TOC visit.

  8. Duration of Hospitalization [ Time Frame: From the first admission date to the discharge date (from 4 to 71 days after start of study medication) ]
    Duration of hospitalization in the per protocol population.

  9. Duration of Hospitalization Postoperatively [ Time Frame: Duration of hospitalization after the first surgery until discharge date (from 4 to 71 days after start of study medication) ]
    Duration of hospitalization after the first surgery until discharge in the per protocol population.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hospitalized men or women >/=18 years of age
  • Expected duration of treatment with intravenous antibiotics anticipated to be >/= 5 full days but not exceeding 14 days
  • Ability to provide documented and signed written informed consent

  • Confirmed or suspected intra abdominal infection defined as follows:

    • For a confirmed intra abdominal infection, a surgical procedure (laparotomy or laparoscopy) must have been performed within 24 hours prior to enrollment and reveal at least one of the following:

      • Gross peritoneal inflammation with purulent exudates (i.e. peritonitis)
      • Intra abdominal abscess
      • Macroscopic intestinal perforation with localized or diffuse peritonitis

  • Subjects enrolled on the basis of a suspected intra abdominal infection must have:

    • Radiological evidence [abdominal plain films, computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound] of gastrointestinal perforation or intra-abdominal abscess and the following signs and symptoms:

      • Symptoms referable to the abdominal cavity (e.g. anorexia, nausea, vomiting or pain), lasting for at least 24 hours
      • Tenderness (with or without rebound), involuntary guarding, absent or diminished bowel sounds, or abdominal wall rigidity

    • At least two of the following SIRS criteria:

      • Temperature > 38.0°C rectal or tympanic membrane, or temperature < 36.0°C rectal or tympanic
      • Heart rate > 90/min
      • Respiratory rate > 20/min
      • WBC >12,000 cells/mm3 or < 4,000 cells/ mm3
    • The subject must be scheduled for a surgical procedure (laparotomy or laparoscopy) within 24 hours of enrollment of the study

Exclusion Criteria:

  • Known hypersensitivity to quinolones, and/or to carbapenems and/or to any other type of beta lactam antibiotic drugs (e.g. penicillins or cephalosporins), or any of the excipients
  • Women who are pregnant or lactating or in whom pregnancy cannot be excluded
  • History of tendon disease/disorder related to quinolone treatment
  • Known congenital or documented acquired QT prolongation; uncorrected hypokalemia; clinically relevant bradycardia; clinically relevant heart failure with reduced left ventricular ejection fraction; previous history of symptomatic arrhythmias
  • Concomitant use of any of the following drugs, reported to increase the QT interval: antiarrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide) or antiarrhythmics class III (e.g., amiodarone, sotalol, dofetilide, ibutilide), neuroleptics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride), tricyclic antidepressive agents, certain antimicrobials (sparfloxacin, erythromycin IV, pentamidine, antimalarials, particularly halofantrine), certain antihistaminics (terfenadine, astemizole, mizolastine), and others (cisapride, vincamine IV, bepridil, diphemanil)
  • Known severe end stage liver disease
  • Creatinine clearance </= 30 mL/min/1.73 m2
  • Systemic antibacterial therapy administered for more than 24 hours within 7 days of enrollment
  • Need for systemic antibacterial therapy with agents other than those described in the study protocol
  • Indwelling peritoneal catheter
  • Pre existing ascites and presumed spontaneous bacterial peritonitis
  • Perforation of the stomach or duodenum, if the duration of perforation is less than 24 hours or if operated on within 24 hours of perforation
  • Perforation of the small bowel (excluding the duodenum) or large bowel, if the duration of perforation is less than 12 hours or if operated on within 12 hours of perforation
  • All pancreatic processes including pancreatic sepsis, peri-pancreatic sepsis, or an intra abdominal infection secondary to pancreatitis
  • Liver and splenic abscess
  • Transmural bowel ischemia or necrosis without perforation or established peritonitis or abscess
  • Acute and gangrenous cholecystitis without perforation
  • Acute cholangitis
  • Early acute, suppurative, or gangrenous non-perforated appendicitis
  • Subjects requiring antibiotic irrigations of the abdominal cavity or surgical wound
  • Treatment with "open abdomen" or marsupialization, or multiple planned re laparotomies
  • Infections originating from the female genital tract
  • Peri-nephric infections
  • Evidence of sepsis with shock requiring the administration of vasopressors for more than 4 consecutive hours
  • Known rapidly fatal underlying disease (death expected within 6 months)
  • Neutropenia (neutrophil count < 1,000/mL) caused by immunosuppressive therapy or malignancy
  • Receiving chronic treatment with known immunosuppressant therapy (including chronic treatment with > 15 mg/day of systemic prednisone or equivalent)
  • Subjects known to have AIDS (CD4 count < 200/mL) or HIV seropositives who are receiving HAART (HIV positive subjects may be included. HIV testing is not required for this study protocol)
  • Subjects with a malignant or pre malignant hematological condition, including Hodgkin's disease and non-Hodgkin lymphoma (subjects with solid tumor can be included in the study)
  • Subjects with a Body Mass Index >/= 45 kg/m2
  • Previous enrollment in this study
  • Participation in any clinical investigational drug study within the previous 4 weeks
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00492726


Locations
Show Show 52 study locations
Sponsors and Collaborators
Bayer
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications of Results:

Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT00492726    
Other Study ID Numbers: 11976
2006-000874-56 ( EudraCT Number )
First Posted: June 27, 2007    Key Record Dates
Results First Posted: March 3, 2010
Last Update Posted: November 7, 2014
Last Verified: November 2014
Keywords provided by Bayer:
Complicated Intra-Abdominal Infections
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
Communicable Diseases
Intraabdominal Infections
Disease Attributes
Pathologic Processes
Moxifloxacin
Ertapenem
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
 Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptive Agents, Hormonal
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female